α-Synuclein strain propagation is independent of cellular prion protein expression in a transgenic synucleinopathy mouse model

PLoS Pathog. 2024 Sep 12;20(9):e1012517. doi: 10.1371/journal.ppat.1012517. eCollection 2024 Sep.

Abstract

The cellular prion protein, PrPC, has been postulated to function as a receptor for α-synuclein, potentially facilitating cell-to-cell spreading and/or toxicity of α-synuclein aggregates in neurodegenerative disorders such as Parkinson's disease. Previously, we generated the "Salt (S)" and "No Salt (NS)" strains of α-synuclein aggregates that cause distinct pathological phenotypes in M83 transgenic mice overexpressing A53T-mutant human α-synuclein. To test the hypothesis that PrPC facilitates the propagation of α-synuclein aggregates, we produced M83 mice that either express or do not express PrPC. Following intracerebral inoculation with the S or NS strain, the absence of PrPC in M83 mice did not prevent disease development and had minimal influence on α-synuclein strain-specified attributes such as the extent of cerebral α-synuclein deposition, selective targeting of specific brain regions and cell types, the morphology of induced α-synuclein deposits, and the structural fingerprints of protease-resistant α-synuclein aggregates. Likewise, there were no appreciable differences in disease manifestation between PrPC-expressing and PrPC-lacking M83 mice following intraperitoneal inoculation of the S strain. Interestingly, intraperitoneal inoculation with the NS strain resulted in two distinct disease phenotypes, indicative of α-synuclein strain evolution, but this was also independent of PrPC expression. Overall, these results suggest that PrPC plays at most a minor role in the propagation, neuroinvasion, and evolution of α-synuclein strains in mice that express A53T-mutant human α-synuclein. Thus, other putative receptors or cell-to-cell propagation mechanisms may have a larger effect on the spread of α-synuclein aggregates during disease.

MeSH terms

  • Animals
  • Brain / metabolism
  • Brain / pathology
  • Disease Models, Animal
  • Humans
  • Mice
  • Mice, Transgenic
  • PrPC Proteins / genetics
  • PrPC Proteins / metabolism
  • Synucleinopathies* / metabolism
  • Synucleinopathies* / pathology
  • alpha-Synuclein* / genetics
  • alpha-Synuclein* / metabolism

Substances

  • alpha-Synuclein
  • PrPC Proteins

Grants and funding

This work was supported by grants to JCW from the Scottish Rite Charitable Foundation of Canada (#18119) (https://srcf.ca/) and the Canadian Institutes of Health Research (PJT-169042) (https://cihr-irsc.gc.ca/). The funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.